Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Immunotherapy, which takes advantage of the immune system to eliminate cancer cells, has been widely studied and applied in oncology. Immune checkpoint inhibitors (ICIs) prevent the immune system from being turned off before cancer cells are eliminated. They have proven to be among the most promisin...
Saved in:
Main Authors: | Pan Shen (Author), Liang Han (Author), Xin Ba (Author), Kai Qin (Author), Shenghao Tu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resistance to immune checkpoint inhibitors in gastric cancer
by: Kai Liu, et al.
Published: (2023) -
Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023) -
Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024) -
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020) -
Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023)